• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SPL
Click for more information
0.00% 10.5¢

STARPHARMA HOLDINGS LIMITED - Announcements

Market Cap $43.82M  ! watchlist Created with Sketch. Add to my watchlist

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The... Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
SPL Shareholder Update January 2017PRICE SENSITIVE19/01/17
SPL VivaGel BV granted QIDP and Fast Track designation by US FDAPRICE SENSITIVE12/01/17
SPL Starpharma receives $3.5M R&D tax incentive refundPRICE SENSITIVE22/12/16
SPL Change in Director's Interest Notice - J Fairley05/12/16
SPL Appendix 3B05/12/16
SPL Change in Director's Interest Notice - R Thomas05/12/16
SPL 2016 AGM Results29/11/16
SPL AGM - Chairman address and CEO presentation29/11/16
SPL Starpharma signs license for VivaGel Condom in IranPRICE SENSITIVE28/11/16
SPL Starpharma to present at Bio-Europe conference08/11/16
SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX PRICE SENSITIVE28/10/16
SPL Additional Priostar Glyphosate Patent Allowed in US-SPL.AX PRICE SENSITIVE28/10/16
SPL Starpharma to present at US Drug Delivery Conference-SPL.AX 26/10/16
SPL Notice of Annual General Meeting/Proxy Form-SPL.AX 26/10/16
SPL Starpharma to present at ASX Spotlight in Asia-SPL.AX 25/10/16
SPL Change in Director's Interest Notice - R Thomas-SPL.AX 17/10/16
SPL Change in Director's Interest Notice - J Fairley-SPL.AX 13/10/16
SPL Appendix 3B-SPL.AX 13/10/16
SPL Enrolment complete for Phase 3 VivaGel BV-R program-SPL.AX PRICE SENSITIVE13/10/16
SPL Change in Director's Interest Notice - J Fairley-SPL.AX 07/10/16
SPL Appendix 3B-SPL.AX 07/10/16
SPL Notification of AGM date-SPL.AX 03/10/16
SPL Change in Director's Interest Notice - R Thomas-SPL.AX 19/09/16
SPL Change in substantial holding-SPL.AX 14/09/16
SPL VivaGel condom receives regulatory approval in Canada-SPL.AX PRICE SENSITIVE13/09/16
SPL Appendix 4E - Correction to NTA Backing-SPL.AX 31/08/16
SPL Starpharma Highlights of FY2016 Presentation-SPL.AX 30/08/16
SPL Appendix 4G - Corporate Governance Statement-SPL.AX 29/08/16
SPL Annual report and full year financial results-SPL.AX PRICE SENSITIVE29/08/16
SPL New DEP drug delivery program initiated with AstraZeneca-SPL.AX PRICE SENSITIVE28/07/16
SPL Starpharma signs license for a VivaGel condom in China-SPL.AX PRICE SENSITIVE21/07/16
SPL Appendix 4C - Quarterly Cashflow Reoprt-SPL.AX PRICE SENSITIVE14/07/16
SPL Change in substantial holding-SPL.AX 14/06/16
SPL Starpharma's DEP eliminates cabazitaxel neutropenia-SPL.AX PRICE SENSITIVE25/05/16
SPL Change in Director's Interest Notice - R Thomas-SPL.AX 19/05/16
SPL Starpharma to present at ASX CEO Session-SPL.AX 17/05/16
SPL Australian Olympic Team taking Dual Protect VivaGel Condoms,ANN-SPL.AX 16/05/16
SPL VivaGel active against Zika virus-SPL.AX PRICE SENSITIVE05/05/16
SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX PRICE SENSITIVE28/04/16
SPL Shareholder Update April 2016-SPL.AX 13/04/16
SPL Starpharma to present at Bio-Europe conference-SPL.AX 05/04/16
SPL DEP cabazitaxel shows complete, sustained tumour regression-SPL.AX PRICE SENSITIVE04/04/16
SPL Adama Licenses Starpharma's Priostar for Novel 2,4-DPRICE SENSITIVE17/03/16
SPL Starpharma licences VivaGel BV to Aspen for ANZPRICE SENSITIVE04/03/16
SPL Change in substantial holding24/02/16
SPL Interim Report and Half-Year Financial ResultsPRICE SENSITIVE17/02/16
SPL Targeted DEP shows sustained superior performancePRICE SENSITIVE02/02/16
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE28/01/16
SPL Change in Director's Interest Notice - Z Peach27/01/16
SPL Change in Director's Interest Notice - P Turvey27/01/16
SPL Change in Director's Interest Notice - J Fairley27/01/16
SPL Change in Director's Interest Notice - R Thomas27/01/16
SPL Appendix 3B25/01/16
SPL Appendix 3B - SPP22/01/16
SPL Starpharma raises $1.9M under Share Purchase PlanPRICE SENSITIVE20/01/16
SPL Change in Director's Interest Notice - R Thomas22/12/15
SPL Change in substantial holding18/12/15
SPL Share Purchase Plan Offer Documents16/12/15
SPL Cleansing Statement16/12/15
SPL Appendix 3B - Share Placement16/12/15
SPL Starpharma signs MOU for VivaGel condom in ChinaPRICE SENSITIVE16/12/15
SPL Change in substantial holding15/12/15
SPL Starpharma completes A$32 million placementPRICE SENSITIVE09/12/15
SPL Trading HaltPRICE SENSITIVE07/12/15
SPL Change in Director's Interest Notice - J Fairley04/12/15
SPL Appendix 3B04/12/15
SPL Second DEP candidate selected by AstraZeneca02/12/15
SPL Retirement of Director Peter Jenkins and Appendix 3Z19/11/15
SPL 2015 AGM results19/11/15
SPL AGM - Chair address and CEO presentation19/11/15
SPL DEP outperforms leading treatments in ovarian cancer modelPRICE SENSITIVE16/11/15
SPL Starpharma receives $3.4M R&D tax incentivePRICE SENSITIVE12/11/15
SPL Starpharma to present at BioEurope conference04/11/15
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE30/10/15
SPL Shareholder Update October 201529/10/15
SPL Notice of Annual General Meeting/Proxy Form16/10/15
SPL Additional US Patent Granted for VivaGel BVPRICE SENSITIVE14/10/15
SPL Change in Director's Interest Notice - J Fairley09/10/15
SPL Appendix 3B09/10/15
SPL OTCQX Life Sciences Presentation01/10/15
SPL Appendix 3B28/09/15
SPL Change in Director's Interest Notice - R Thomas28/09/15
SPL EU Marketing Approval Granted for VivaGel BVPRICE SENSITIVE24/09/15
SPL Date of Annual General Meeting21/09/15
SPL Change in Director's Interest Notice - R Hazleton21/09/15
SPL Change in Director's Interest Notice - P Turvey10/09/15
SPL Change in Director's Interest Notice - Z Peach09/09/15
SPL Change in Director's Interest Notice - J Fairley09/09/15
SPL Change in Director's Interest Notice - R Thomas09/09/15
SPL Drug delivery license with AstraZeneca conference call07/09/15
SPL Starpharma signs drug delivery license with AstraZenecaPRICE SENSITIVE07/09/15
SPL Annual report and full year financial resultsPRICE SENSITIVE21/08/15
SPL Appendix 4G - Corporate Governance Statement21/08/15
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE30/07/15
SPL Change in substantial holding30/06/15
SPL Becoming a substantial holder10/06/15
SPL Change in Director's Interest Notice - J Fairley27/05/15
SPL Change in substantial holding08/05/15
SPL AstraZeneca to develop oncology drug using DEP technology04/05/15
SPL Ceasing to be a substantial holder01/05/15
SPL Shareholder Update January 2017
19/01/17PRICE SENSITIVE
SPL VivaGel BV granted QIDP and Fast Track designation by US FDA
12/01/17PRICE SENSITIVE
SPL Starpharma receives $3.5M R&D tax incentive refund
22/12/16PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley
05/12/16
SPL Appendix 3B
05/12/16
SPL Change in Director's Interest Notice - R Thomas
05/12/16
SPL 2016 AGM Results
29/11/16
SPL AGM - Chairman address and CEO presentation
29/11/16
SPL Starpharma signs license for VivaGel Condom in Iran
28/11/16PRICE SENSITIVE
SPL Starpharma to present at Bio-Europe conference
08/11/16
SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX
28/10/16PRICE SENSITIVE
SPL Additional Priostar Glyphosate Patent Allowed in US-SPL.AX
28/10/16PRICE SENSITIVE
SPL Starpharma to present at US Drug Delivery Conference-SPL.AX
26/10/16
SPL Notice of Annual General Meeting/Proxy Form-SPL.AX
26/10/16
SPL Starpharma to present at ASX Spotlight in Asia-SPL.AX
25/10/16
SPL Change in Director's Interest Notice - R Thomas-SPL.AX
17/10/16
SPL Change in Director's Interest Notice - J Fairley-SPL.AX
13/10/16
SPL Appendix 3B-SPL.AX
13/10/16
SPL Enrolment complete for Phase 3 VivaGel BV-R program-SPL.AX
13/10/16PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley-SPL.AX
07/10/16
SPL Appendix 3B-SPL.AX
07/10/16
SPL Notification of AGM date-SPL.AX
03/10/16
SPL Change in Director's Interest Notice - R Thomas-SPL.AX
19/09/16
SPL Change in substantial holding-SPL.AX
14/09/16
SPL VivaGel condom receives regulatory approval in Canada-SPL.AX
13/09/16PRICE SENSITIVE
SPL Appendix 4E - Correction to NTA Backing-SPL.AX
31/08/16
SPL Starpharma Highlights of FY2016 Presentation-SPL.AX
30/08/16
SPL Appendix 4G - Corporate Governance Statement-SPL.AX
29/08/16
SPL Annual report and full year financial results-SPL.AX
29/08/16PRICE SENSITIVE
SPL New DEP drug delivery program initiated with AstraZeneca-SPL.AX
28/07/16PRICE SENSITIVE
SPL Starpharma signs license for a VivaGel condom in China-SPL.AX
21/07/16PRICE SENSITIVE
SPL Appendix 4C - Quarterly Cashflow Reoprt-SPL.AX
14/07/16PRICE SENSITIVE
SPL Change in substantial holding-SPL.AX
14/06/16
SPL Starpharma's DEP eliminates cabazitaxel neutropenia-SPL.AX
25/05/16PRICE SENSITIVE
SPL Change in Director's Interest Notice - R Thomas-SPL.AX
19/05/16
SPL Starpharma to present at ASX CEO Session-SPL.AX
17/05/16
SPL Australian Olympic Team taking Dual Protect VivaGel Condoms,ANN-SPL.AX
16/05/16
SPL VivaGel active against Zika virus-SPL.AX
05/05/16PRICE SENSITIVE
SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX
28/04/16PRICE SENSITIVE
SPL Shareholder Update April 2016-SPL.AX
13/04/16
SPL Starpharma to present at Bio-Europe conference-SPL.AX
05/04/16
SPL DEP cabazitaxel shows complete, sustained tumour regression-SPL.AX
04/04/16PRICE SENSITIVE
SPL Adama Licenses Starpharma's Priostar for Novel 2,4-D
17/03/16PRICE SENSITIVE
SPL Starpharma licences VivaGel BV to Aspen for ANZ
04/03/16PRICE SENSITIVE
SPL Change in substantial holding
24/02/16
SPL Interim Report and Half-Year Financial Results
17/02/16PRICE SENSITIVE
SPL Targeted DEP shows sustained superior performance
02/02/16PRICE SENSITIVE
SPL Appendix 4C - Quarterly Cashflow Report
28/01/16PRICE SENSITIVE
SPL Change in Director's Interest Notice - Z Peach
27/01/16
SPL Change in Director's Interest Notice - P Turvey
27/01/16
SPL Change in Director's Interest Notice - J Fairley
27/01/16
SPL Change in Director's Interest Notice - R Thomas
27/01/16
SPL Appendix 3B
25/01/16
SPL Appendix 3B - SPP
22/01/16
SPL Starpharma raises $1.9M under Share Purchase Plan
20/01/16PRICE SENSITIVE
SPL Change in Director's Interest Notice - R Thomas
22/12/15
SPL Change in substantial holding
18/12/15
SPL Share Purchase Plan Offer Documents
16/12/15
SPL Cleansing Statement
16/12/15
SPL Appendix 3B - Share Placement
16/12/15
SPL Starpharma signs MOU for VivaGel condom in China
16/12/15PRICE SENSITIVE
SPL Change in substantial holding
15/12/15
SPL Starpharma completes A$32 million placement
09/12/15PRICE SENSITIVE
SPL Trading Halt
07/12/15PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley
04/12/15
SPL Appendix 3B
04/12/15
SPL Second DEP candidate selected by AstraZeneca
02/12/15
SPL Retirement of Director Peter Jenkins and Appendix 3Z
19/11/15
SPL 2015 AGM results
19/11/15
SPL AGM - Chair address and CEO presentation
19/11/15
SPL DEP outperforms leading treatments in ovarian cancer model
16/11/15PRICE SENSITIVE
SPL Starpharma receives $3.4M R&D tax incentive
12/11/15PRICE SENSITIVE
SPL Starpharma to present at BioEurope conference
04/11/15
SPL Appendix 4C - Quarterly Cashflow Report
30/10/15PRICE SENSITIVE
SPL Shareholder Update October 2015
29/10/15
SPL Notice of Annual General Meeting/Proxy Form
16/10/15
SPL Additional US Patent Granted for VivaGel BV
14/10/15PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley
09/10/15
SPL Appendix 3B
09/10/15
SPL OTCQX Life Sciences Presentation
01/10/15
SPL Appendix 3B
28/09/15
SPL Change in Director's Interest Notice - R Thomas
28/09/15
SPL EU Marketing Approval Granted for VivaGel BV
24/09/15PRICE SENSITIVE
SPL Date of Annual General Meeting
21/09/15
SPL Change in Director's Interest Notice - R Hazleton
21/09/15
SPL Change in Director's Interest Notice - P Turvey
10/09/15
SPL Change in Director's Interest Notice - Z Peach
09/09/15
SPL Change in Director's Interest Notice - J Fairley
09/09/15
SPL Change in Director's Interest Notice - R Thomas
09/09/15
SPL Drug delivery license with AstraZeneca conference call
07/09/15
SPL Starpharma signs drug delivery license with AstraZeneca
07/09/15PRICE SENSITIVE
SPL Annual report and full year financial results
21/08/15PRICE SENSITIVE
SPL Appendix 4G - Corporate Governance Statement
21/08/15
SPL Appendix 4C - Quarterly Cashflow Report
30/07/15PRICE SENSITIVE
SPL Change in substantial holding
30/06/15
SPL Becoming a substantial holder
10/06/15
SPL Change in Director's Interest Notice - J Fairley
27/05/15
SPL Change in substantial holding
08/05/15
SPL AstraZeneca to develop oncology drug using DEP technology
04/05/15
SPL Ceasing to be a substantial holder
01/05/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $43.82M
Open High Low Value Volume
10.5¢ 11.5¢ 10.0¢ $110.6K 1.006M

Buyers (Bids)

No. Vol. Price($)
1 83046 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 30000 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
10.5¢ 		  Change
0.000 ( 5.00 %)
Open High Low Volume
10.3¢ 11.5¢ 10.3¢ 347942
Last updated 15.58pm 15/11/2024 ?
SPL (ASX) Chart

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.